Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
9.58
+0.03 (0.31%)
At close: Aug 13, 2025, 4:00 PM
9.45
-0.13 (-1.36%)
After-hours: Aug 13, 2025, 6:38 PM EDT

Sagimet Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Revenue
--2---
Upgrade
Gross Profit
--2---
Upgrade
Selling, General & Admin
17.4316.0112.966.144.383.22
Upgrade
Research & Development
49.4638.4419.7824.9219.348.18
Upgrade
Operating Expenses
66.8954.4532.7431.0623.7211.4
Upgrade
Operating Income
-66.89-54.45-30.74-31.06-23.72-11.4
Upgrade
Interest & Investment Income
8.898.892.860.550.030.03
Upgrade
Other Non Operating Income (Expenses)
-1.38-00-0.75-
Upgrade
EBT Excluding Unusual Items
-59.38-45.57-27.88-30.5-24.44-11.37
Upgrade
Pretax Income
-59.38-45.57-27.88-30.5-24.44-11.37
Upgrade
Net Income
-59.38-45.57-27.88-30.5-24.44-11.37
Upgrade
Net Income to Common
-59.38-45.57-27.88-30.5-24.44-11.37
Upgrade
Shares Outstanding (Basic)
323110000
Upgrade
Shares Outstanding (Diluted)
323110000
Upgrade
Shares Change (YoY)
25.80%199.71%5565.90%50.61%26.95%-
Upgrade
EPS (Basic)
-1.84-1.45-2.66-165.20-199.40-117.75
Upgrade
EPS (Diluted)
-1.85-1.45-2.66-165.20-199.40-117.75
Upgrade
Gross Margin
--100.00%---
Upgrade
Operating Margin
---1537.00%---
Upgrade
Profit Margin
---1393.80%---
Upgrade
EBITDA
------11.4
Upgrade
D&A For EBITDA
-----0
Upgrade
EBIT
-66.89-54.45-30.74-31.06-23.72-11.4
Upgrade
Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q